Shares of Gilead Sciences have skyrocketed over the past two years, propelling the company into the upper echelons of the healthcare sector in terms of market cap. With all of its new peer group offering a dividend, should Gilead follow suit?
Shares of Gilead Sciences have skyrocketed over the past two years, propelling the company into the upper echelons of the healthcare sector in terms of market cap. With all of its new peer group offering a dividend, should Gilead follow suit?